Results from a first-in-human study of dersimelagon, an investigational oral selective mc1r agonist

HIGHLIGHTS

• who: Akihito Ogasawara from the Mitsubishi Tanabe Pharma Corporation, u20111u20111, Marunouchi Chiyodau2011ku, Tokyo, u20118205, Japan have published the paper: Results from a first-in-human study of dersimelagon, an investigational oral selective MC1R agonist, in the Journal: (JOURNAL)
• what: The authors report the results of a first-in-human phase 1 double-blind, placebo-controlled study (ClinicalTrials.gov ID: NCT02834442) that evaluated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending oral doses of dersimelagon in healthy participants, including effects of sex, age, and race on the PK profile of dersimelagon . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.